CRE Surveillance Data from France
![](https://i0.wp.com/allphasepharma.com/dir/wp-content/uploads/2014/10/CLSI-EUCAST-slider-copy.jpg?resize=640%2C200&ssl=1)
Despite all the concern about the emergence of CRE pathogens worldwide, it is quite difficult to obtain hard quantitative, prospectively collected incidence figures. A recent article by Robert [1] and colleagues provides useful data from France. Using a practical definition of carbapenem-non-susceptibility Continue reading CRE Surveillance Data from France